GFAP and Parkinson disease: They discovered that baseline plasma GFAP concentrations were significantly higher in the MCI conversion group (PD patients who developed from MCI to dementia during the entire follow-up period) than in the MCI stable group (PD patients who did not develop from MCI to dementia during the entire follow-up period).